x
ServiziMenu principaleHome
You are here: Home > Events > Past events > 2021 > ONLINE EVENT: 5th ESO-ESMO-RCE Clinical Update on Rare Adult Solid Cancers
Print

Description

Due to the current situation with COVID-19 we have decided that the event will be held online.
Please, find out the latest information about this online course on www.e-ESO.net.


Chairs:
J.Y. Blay, FR - P.G. Casali, IT - R.A. Stahel, CH

The “ESO-ESMO-RCE Clinical Update on Rare Adult Solid Cancers” is an educational effort held on an annual basis and conceived to strengthen the education of medical professionals willing to devote their career to rare cancers.
Despite being rare as single entities, rare adult solid cancers account for as many as 15% of all new cancer cases, thus being the main group within rare cancers in general. The definition of rare cancers by the RARECARE project and the list of the 10 “families” of rare adult solid cancers gave rise to shape the sessions of this course:

• Head & neck cancers
• Sarcomas
• Rare thoracic tumors
• Neuroendocrine tumors
• Central nervous system neoplasms
• Rare female genital cancers
• Endocrine gland tumors
• Digestive rare cancers
• Rare urological and male genital tumors
• Rare skin cancers & non-cutaneous melanoma

Since ‘networking’ and ‘multidisciplinarity’ are the two main keywords to improve the quality of care of rare cancers, ESO has decided to develop the programme of this course in collaboration with other the European initiatives in this field and to give its contribution to tackle the rare cancer issue. The 5th ESO-ESMO-RCE Clinical Update on Rare Adult Solid Cancers is conceived in the context of, and supported by, EURACAN, the European Reference Network on rare adult solid cancers. The Faculty has been largely selected from EURACAN, also with the aim of letting this educational effort closely interact with its networking activities.

Optimal management of rare adult solid cancers poses specific diagnostic and therapeutic challenges. The sessions of the course have been designed to address the needs of clinical oncologists wanting an update on recent advancements on these tumours.

The global health crisis caused by the Covid-19 pandemic has forced us to turn the in-person course into a virtual event. It will be a good opportunity to receive updates on the available evidence in this field and promote future networking and collaborations.

We have done our best to design an online course enabling participants to attend according to their own schedule. There will be a mixture of pre-recorded sessions and live sessions for Q & A and clinical case discussions with faculty members and moderators.

Paolo Casali
On behalf of the co-Chairs

LEARNING OBJECTIVES
Provide an update on the latest developments in the area of rare adult solid rare cancers, with a background perspective on state-of-the-art and evidence based practice.

INFORMATION
The course will be carried out in two different steps:

Step 1

Pre-recorded sessions will be made available from 1st December 2020 and will remain on the e-eso website. You will be able to see all the sessions in your own time, and send questions that will be selected for discussion during Step 2 of the course;

Step 2
Live sessions with an introductory round table on rare cancers in general, clinical case presentations and Q&A discussions with moderators and speakers will be held on 16 and 17 January 2021.
During the Q&A sessions, speakers will answer and discuss a number of selected questions received in advance via email (see below for instructions) and/or during the live streaming via chat.

Q&A SESSIONS
Participants are encouraged to send questions in advance, as long as they listen to the recorded sessions. The moderators will select questions to be answered during the live streaming. Questions should be sent to raretumours@eso.net, no later than 4 January 2021. Please indicate the session title and speaker your question refers to.

All the contents will be recorded and accessible via the e-ESO website after the event (registration to access the contents will remain open).

The course is an ESO-ESMO-RCE joint event          
RCE         ESMO
Held in collaboration with          
 INT          
In partnership with
         
         

 

Faculty

INVITED FACULTY
Tit Albreht, National Institute of Public Health, ., Ljubljana, SI
Martina Angi, Fondazione IRCCS Istituto Nazionale Tumori, Milan, IT
Giulia Arrivi, Azienda Ospedaliero Universitaria Sant'Andrea, La Sapienza, Unità di Oncologia, Roma, IT
Stefanie Aust, Medical University of Vienna, AT
Judith Balmana, Vall d'Hebron Institute of Oncology, Medical Oncology Dept., Barcelona, ES
Eric Baudin, Institut Gustave-Roussy, Dept. of Nuclear Medicine and Endocrine Tumors, Villejuif, FR
Alfredo Berruti, ASST Spedali Civili, Brescia, IT
Jean-Yves Blay, Centre Léon Bérard, Lyon, FR
Jaume Capdevila, Vall d'Hebron University Hospital, Barcelona, ES
Martyn Caplin, Royal Free Hospital, London, UK
Paolo Giovanni Casali, Fondazione IRCCS Istituto Nazionale Tumori, Milan, IT
Stefano Cavalieri, Fondazione IRCCS Istituto Nazionale Tumori, Milan, IT
Elena Colombo, IRCCS Istituto Nazionale Dei Tumori, Oncologia Medica 3, Milan, IT
Filippo De Braud, Fondazione IRCCS Istituto Nazionale Tumori, Milan, IT
Loris De Cecco, Fondazione IRCCS Istituto Nazionale Tumori, Milan, IT
Christelle de la Fouchardiere, Centre Léon Bérard, Lyon, FR
Francesco De Lorenzo, ECPC, European Cancer Patient Coalition, Brussels, BE
Marcello Deraco, Fondazione IRCCS Istituto NazionaleTumori, Milan, IT
Alexandru Eniu, Riviera-Chablais Vaud-Valais, Interdisciplinary Oncology Service (SIC), Rennaz, CH
Nicola Fazio, European Institute of Oncology, Milan, IT
Silvia Franceschi, Centro Riferimento Oncologico, Struttura Complessa Epidemiologia Oncologica, Aviano, IT
Anna Maria Frezza, Fondazione IRCCS Istituto NazionaleTumori, Milan, IT
Giulia Galli, Fondazione IRCCS Istituto Nazionale dei Tumori, Medical Oncology Dpt., Milano, IT
Marina Garassino, Fondazione IRCCS Istituto Nazionale Tumori, Milan, IT
Jourik A. Gietema, University Medical Center, Groningen, NL
Robert Glynne-Jones, Mount Vernon Centre for Cancer Treatment, London, UK
Vincent Gregoire, Centre Léon Bérard, Lyon, FR
Alessandro Gronchi, Fondazione IRCCS Istituto Nazionale Tumori, Milan, IT
Ellen Kapiteijn, University Medical Center, Leiden, NL
Heinz-Josef Klumpen, University of Amsterdam UMC, ., Amsterdam, NL
Ruth Ladenstein, St.Anna-Kinderspital, Children’s Cancer Research Institute, Vienna, AT
Celeste Lebbé, Saint Louis Hospital, Paris, FR
Lisa Licitra, Fondazione IRCCS Istituto Nazionale Tumori, Milan, IT
Laura Deborah Locati, Fondazione IRCCS Istituto Nazionale Tumori, Milan, IT
Domenica Lorusso, Policlinico Universitario Gemelli, Unità di Oncologia Ginecologica, Roma, IT
Andrea Necchi, National Cancer Institute - IRCCS Foundation, Medical Oncology Dept., Milan, IT
Monica Niger, Fondazione IRCCS Istituto Nazionale Tumori, Milan, IT
Kathy Oliver, International Brain Tumour Alliance, Tadworth, UK
Fedro Alessandro Peccatori, European Institute of Oncology, Milan, IT
Alessia Pellerino, City of Health and Science University Hospital, Dept. of Neuro-Oncology, Turin, IT
Cesare Piazza, Fondazione IRCCS Istituto Nazionale Tumori, Milan, IT
Sophie Piperno-Neumann, Curie Institute, Paris, FR
Isabelle Ray-Coquard, Centre Léon Bérard, Lyon, FR
Carlo Resteghini, Fondazione IRCCS Istituto Nazionali Tumori, Milan, IT
Michael Seckl, Imperial College Hammersmith Campus, London, UK
Christian Simon, Centre Hospitalier Universitaire Vaudois, Lausanne, CH
Riccardo Soffietti, City of Health and Science University Hospital, Torino, IT
Silvia Stacchiotti, Fondazione IRCCS Istituto Nazionale Tumori, Milan, IT
Rolf A. Stahel, Comprehensive Cancer Center University Hospital, Zurich, CH
Sandra Strauss, UCL Cancer Institute, Medical Oncology Dept., London, GB
Thais Tong, Leiden University Medical Center, Medical Oncology Dept., Leiden, NL
Annalisa Trama, Fondazione IRCCS Istituto Nazionale Tumori, Milan, IT
Martin J. Van den Bent, Erasmus M.C. Cancer Center, Rotterdam, NL
Lucjan Wyrwicz, Maria Sklodowska-Curie Memorial Cancer Center, Warsaw, PL

General information

ORGANISING SECRETARIAT
European School of Oncology
Via Turati, 29
20121 Milan, Italy

Marina Fregonese
- Event Organiser - mfregonese@eso.net
Dolores Knupfer - Event Organiser - dknupfer@eso.net
Mariachiara Deleo - e-ESO Assistant - mdeleo@eso.net
Francesca Marangoni - e-ESO Executive Manager - fmarangoni@eso.net

OFFICIAL LANGUAGE
The official language is English. Translation will not be provided.

CME ACCREDITATION CERTIFICATES
Participants will be issued a certificate of attendance (minimum attendance: 75% of the entire course). An online evaluation questionnaire and learning assessment test will need to be completed in order to get the certficate that will be issued by email.
Application for CME recognition has been submitted to the Accreditation Council of Oncology in Europe (ACOE) and 24 CME credits have been granted to this event. The American Medical Association (AMA) and the Accreditation Council for Continuous Medical Education (ACCME) designate this type of educational activity for a maximum of 1 AMA PRA category 1 credits per hour of activity.

ESCO CREDITS



The Course enables ESCO students to earn ESCO credits and therefore access more ESCO benefits. Full and active participation in the Course earns participants 22 ESCO credits.
Visit www.esco.org for information on how to join ESCO.

Registration

IDEAL PARTICIPANT’S PROFILE
• Medical degree
• Specialization/residency in medical oncology, radiation oncology, surgical oncology or equivalent

REGISTRATION
Registration for the event is free but mandatory.

REGISTER ONLINE HERE

CONFIRMATION OF REGISTRATION
Registration will be confirmed by e-mail.

All the contents will be recorded and accessible via the e-ESO website during and after the event
(registration to access the contents will remain open after the event).

 

Programme

1 December

 THE JOINT ACTION ON RARE CANCERS: WHAT NEXT?
Pre-recorded sessions available from 1 December 2020
Jean-Yves Blay, FR - Fedro Alessandro Peccatori, IT
  The rare cancer agenda 2030
Paolo Giovanni Casali, IT
  The epidemiology of rare adult solid cancers
Annalisa Trama, IT
  EURACAN: where we are?
Jean-Yves Blay, FR
  An educational pathway on rare adult solid cancers
Anna Maria Frezza, IT
 UPDATE ON RARE THORACIC CANCERS
Pre-recorded sessions available from 1 December 2020
Marina Garassino, IT - Rolf A. Stahel, CH
  Mesothelioma
Rolf A. Stahel, CH
  Thymic tumors
Marina Garassino, IT
 UPDATE ON SARCOMAS
Pre-recorded sessions available from 1 December 2020
Jean-Yves Blay, FR - Paolo Giovanni Casali, IT
  Adult soft tissue sarcomas
Paolo Giovanni Casali, IT
  GIST
Jean-Yves Blay, FR
  Ewing sarcoma and osteosarcoma
Sandra Strauss, UK
  Rare bone and soft tissue sarcomas
Silvia Stacchiotti, IT
  Improving the surgical margin in sarcomas
Alessandro Gronchi, IT
 UPDATE ON HEAD AND NECK CANCERS
Pre-recorded sessions available from 1 December 2020
Vincent Gregoire, FR - Lisa Licitra, IT
  Laryngeal & hypopharyngeal carcinoma
Cesare Piazza, IT
  Oropharyngeal carcinoma
Vincent Gregoire, FR
  Nasopharyngeal carcinoma & sinonasal cancers
Lisa Licitra, IT
  Salivary gland tumors
Laura Deborah Locati, IT
  Oral cavity tumors
Christian Simon, CH
  Advances in molecular biology
Loris De Cecco, IT
 UPDATE ON NEUROENDOCRINE TUMORS
Pre-recorded sessions available from 1 December 2020
Martyn Caplin, UK - Filippo De Braud, IT
  Thoracic NETs
Martyn Caplin, UK
  Gastroenteropancreatic NETs
Nicola Fazio, IT
 UPDATE ON CNS TUMORS
Pre-recorded sessions available from 1 December 2020
Riccardo Soffietti, IT - Martin J. Van den Bent, NL
  Gliomas
Riccardo Soffietti, IT
  Rare CNS tumors
Martin J. Van den Bent, NL
  Hereditary cancer risk syndromes
Judith Balmana, ES
 UPDATE ON ENDOCRINE GLAND TUMORS
Pre-recorded sessions available from 1 December 2020
Christelle de la Fouchardiere, FR - Lisa Licitra, IT
  Adrenal cancer
Alfredo Berruti, IT
  Thyroid cancer
Jaume Capdevila, ES
  The epidemiological evidence of sovradiagnosis
Silvia Franceschi, IT
 UPDATE ON DIGESTIVE RARE CANCERS
Pre-recorded sessions available from 1 December 2020
Filippo De Braud, IT - Lucjan Wyrwicz, PL
  Biliary tumors
Heinz-Josef Klumpen, NL
  Anal carcinoma
Robert Glynne-Jones, UK
  Peritoneal mesothelioma & pseudomyxoma
Marcello Deraco, IT
 UPDATE ON RARE UROGENITAL CANCERS
Pre-recorded sessions available from 1 December 2020
Jourik A. Gietema, NL - Andrea Necchi, IT
  Testicular cancer
Jourik A. Gietema, NL
  Penile cancer
Andrea Necchi, IT
  Survivorship as a healthcare issue
Tit Albreht, SI
  High level views on survivorship. The cancer mission perspective. The commons of paediatric and adult cancer
Ruth Ladenstein, AT
 UPDATE ON RARE FEMALE GENITAL CANCERS
Pre-recorded sessions available from 1 December 2020
Fedro Alessandro Peccatori, IT - Michael Seckl, UK
  Non-epithelial ovarian tumors
Isabelle Ray-Coquard, FR
  Trophoblastic tumors
Michael Seckl, UK
  Vulvar and vaginal cancers
Domenica Lorusso, IT
 UPDATE ON RARE SKIN TUMORS AND UVEAL MELANOMA
Pre-recorded sessions available from 1 December 2020
Ellen Kapiteijn, NL - Sophie Piperno-Neumann, FR
  Merkel cell carcinoma
Celeste Lebbé, FR
  Cutaneous adnexal malignancies
Stefano Cavalieri, IT
  Uveal melanoma
Martina Angi, IT

16 January

11:30LIVE SESSION - THE JOINT ACTION ON RARE CANCER: WHAT NEXT?
Fedro Alessandro Peccatori, IT - Rolf A. Stahel, CH
 11:30Introduction
Fedro Alessandro Peccatori, IT - Rolf A. Stahel, CH
 11:40Round table: The Rare Cancer Agenda 2030
Jean-Yves Blay, FR - Paolo Giovanni Casali, IT - Francesco De Lorenzo, IT - Alexandru Eniu, CH - Kathy Oliver, UK - Annalisa Trama, IT
 12:10Q&A and General discussion
12:40LIVE SESSION - UPDATE ON RARE THORACIC CANCERS
Marina Garassino, IT - Rolf A. Stahel, CH
 12:40Q&A
Marina Garassino, IT - Rolf A. Stahel, CH
 13:00Clinical case discussion
Giulia Galli, IT
13:30LIVE SESSION - UPDATE ON SARCOMAS
Jean-Yves Blay, FR - Paolo Giovanni Casali, IT
 13:30Q&A
Jean-Yves Blay, FR - Paolo Giovanni Casali, IT - Alessandro Gronchi, IT - Silvia Stacchiotti, IT - Sandra Strauss, UK
 13:50Clinical case discussion
Anna Maria Frezza, IT
14:15LIVE SESSION - UPDATE ON HEAD & NECK CANCERS
Vincent Gregoire, FR - Lisa Licitra, IT
 14:15Q&A
Loris De Cecco, IT - Vincent Gregoire, FR - Lisa Licitra, IT - Laura Deborah Locati, IT - Cesare Piazza, IT - Christian Simon, CH
 14:35Clinical case discussion
Carlo Resteghini, IT
15:00LIVE SESSION - UPDATE ON NEUROENDOCRINE TUMORS
Eric Baudin, FR - Filippo De Braud, IT
 15:00Q&A
Eric Baudin, FR - Filippo De Braud, IT - Nicola Fazio, IT
 15:20Clinical case discussion
Giulia Arrivi, IT
15:45LIVE SESSION - UPDATE ON CNS TUMORS
Riccardo Soffietti, IT - Martin J. Van den Bent, NL
 15:45Q&A
Judith Balmana, ES - Riccardo Soffietti, IT - Martin J. Van den Bent, NL
 16:05Clinical case discussion
Alessia Pellerino, IT

17 January

11:30LIVE SESSION - UPDATE ON ENDOCRINE GLAND TUMORS
Christelle de la Fouchardiere, FR - Lisa Licitra, IT
 11:30Q&A
Alfredo Berruti, IT - Jaume Capdevila, ES - Christelle de la Fouchardiere, FR - Silvia Franceschi, IT - Lisa Licitra, IT
 11:50Clinical case discussion
Elena Colombo, IT
12:15LIVE SESSION - UPDATE ON DIGESTIVE RARE CANCERS
Filippo De Braud, IT - Lucjan Wyrwicz, PL
 12:15Q&A
Filippo De Braud, IT - Marcello Deraco, IT - Robert Glynne-Jones, UK - Heinz-Josef Klumpen, NL - Lucjan Wyrwicz, PL
 12:35Clinical case discussion
Monica Niger, IT
13:00LIVE SESSION - UPDATE ON RARE UROGENITAL CANCERS
Jourik A. Gietema, NL - Andrea Necchi, IT
 13:00Q&A
Tit Albreht, SI - Jourik A. Gietema, NL - Ruth Ladenstein, AT - Andrea Necchi, IT
 13:20Clinical case discussion
13:45LIVE SESSION - UPDATE ON RARE FEMALE GENITAL CANCERS
Fedro Alessandro Peccatori, IT - Michael Seckl, UK
 13:45Q&A
Domenica Lorusso, IT - Fedro Alessandro Peccatori, IT - Isabelle Ray-Coquard, FR - Michael Seckl, UK
 14:05Clinical case discussion
Stefanie Aust, AT
14:30LIVE SESSION - UPDATE ON RARE SKIN TUMORS & UVEAL MELANOMA
Ellen Kapiteijn, NL - Sophie Piperno-Neumann, FR
 14:30Q&A
Martina Angi, IT - Stefano Cavalieri, IT - Ellen Kapiteijn, NL - Celeste Lebbé, FR - Sophie Piperno-Neumann, FR
 14:50Clinical case discussion
Thais Tong, NL
15:05Closing remarks
Paolo Giovanni Casali, IT